Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer

Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer

Background Combining immune checkpoint inhibitors (ICIs) with chemotherapy has become a standard treatment for patients with non-small cell lung cancer (NSCLC) lacking driver gene mutations. Reliable biomarkers are essential for predicting treatment outcomes. Emerging evidence from various cancers s...

Full description

Bibliographic Details
Main Authors: Jun Lu, Ying Li, Wei Zhang, Hua Zhong, Fang Hu, Liang Zheng, Xiaohua Yang, Lin Huang, Xueyan Zhang, Tianqing Chu, Baohui Han, Yinchen Shen, Wei Nie, Jianlin Xu, Shuyuan Wang, Runbo Zhong, Xiaoxuan Zheng
Format: Article
Language:English
Published: BMJ Publishing Group 2024-04-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/4/e008190.full

Internet

https://jitc.bmj.com/content/12/4/e008190.full

Similar Items